2025-11-15 01:51:52
Latest Post
BEL receives orders worth Rs. 871Crore
Rossell Techsys Recognized as Outstanding Supplier by Lockheed Martin
660 MW Unit-1 of SJVN's Buxar Thermal Power Project Successfully achieves Commercial Operation
Adani Cement is the First Indian Cement Company to become a TNFD Adopter
Liberty General Insurance Launches Surety Insurance Business in India
Research
Angel Broking recommends Buy on Sun Pharma with a Target Price of Rs. 706
Posted On : 2014-06-08 20:28:33( TIMEZONE : IST )
Sun Pharmaceutical Industries (Sun Pharma) posted a good set of numbers for 4QFY2014, mostly in line with our expectations on the topline and OPM front, while the net profit came in better than expected. The company posted sales of Rs. 4,044cr V/s an expected Rs. 4,000cr, registering a yoy growth of 31.6%. The OPM came in line of our expectation at 44.5% as against 41.0% in 4QFY2013. The adj. net profit for the quarter came in at Rs. 1,587cr, a yoy growth of 56.9%, and higher than our estimate of Rs. 1,401cr. We recommend a Buy on the stock with a price target of Rs. 706.
Better-than-expected results on net profit front: Sun Pharma posted a good set of numbers for 4QFY2014, mostly in line with our expectations on the top-line and OPM fronts, while the net profit came in higher than our expectation. The company posted sales of Rs. 4,044cr (V/s an expected Rs. 4,000cr), registering a yoy growth of 31.6%. Exports, which grew by 34.8% yoy and domestic markets which grew by 21.4% yoy each, aided sales growth. The OPM came in line of our expectation at 44.5% V/s 41.5% in 4QFY2013. While sales and OPM came in line of our expectation for the quarter, the net profit came in higher than our expectation on back of higher other income, which grew by 90% yoy. The net profit for the quarter came in at Rs. 1587.1cr, a yoy growth of 56.9%, higher than our expectation of Rs. 1,401cr.
Outlook and valuation: Sun Pharma is one of the largest and fastest growing Indian pharmaceutical companies. We expect its net sales to post a 25.4% CAGR (including Ranbaxy Laboratories) to Rs. 38,186cr and EPS to post a 5.3% CAGR to Rs. 32.1 over FY2014–16. We recommend a Buy on the stock with a target price of Rs. 706.
Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.599.35 as compared to the previous close of Rs. 597.85. The total number of shares traded during the day was 173293 in over 5597 trades.
The stock hit an intraday high of Rs. 611.5 and intraday low of 595.9. The net turnover during the day was Rs. 104154236.